Testosterone patch shows promise for menopausal women

A new testosterone patch has shown positive results in initial Phase 1 clinical testing, offering renewed hope for women seeking hormone therapy.
Drug delivery firm Medherant has announced encouraging findings from its Phase 1 trial of the TEPI Patch, carried out at Hammersmith Medicines Research (HMR) in London.
The study found that the patch effectively delivers testosterone through the skin, restoring blood levels to the normal pre-menopausal range.
The development could help address a major gap in treatment options for women going through menopause.
Karolina Afors is medical director of Medherant – the company that developed the patch.
She said: “These latest results represent another major step in the development of the testosterone TEPI Patch to address a significant condition faced by many post-menopausal women.
“Our patch technology will provide women with a superior and convenient treatment option for testosterone as part of menopause hormone therapy.”
Medherant, a clinical-stage spin-out from the University of Warwick, has developed what it says could become the first-in-class testosterone patch designed specifically for women.
Built on its proprietary TEPI Patch technology, it provides strong adhesion, ensuring reliable and comfortable wear throughout daily activities.
The company has secured approval from both the Medicines and Healthcare products Regulatory Agency (MHRA) and the Research Ethics Committee for its clinical trial application to begin the next multiple-dose pharmacokinetic study – a follow-up study testing repeated doses – due to start dosing later this year.
This study focuses on advancing the TEPI Patch as a potential treatment for HSDD.
Medherant has also obtained scientific advice from the MHRA and the Swedish Medical Products Agency to inform its regulatory strategy for product registration in the UK and EU.
David Haddleton is chief scientific officer at Medherant and professor in the Department of Chemistry at the University of Warwick.
He said: “The success of this initial trial paves the way for our upcoming multiple-dose study which starts dosing before the end of the year.
“We remain committed to accelerating development to bring the testosterone TEPI Patch to market swiftly and to deliver the adhesion and comfort that women deserve.”
Despite recommendations in the NICE Menopause Guidelines and the Global Consensus Position Statement on the Use of Testosterone Therapy for Women, there is currently no approved testosterone patch product for women.
Transdermal delivery offers advantages over oral hormone administration by avoiding peaks in drug levels that can lead to side effects, and by allowing better dose control than gels and creams.
Alongside developing its own products, Medherant collaborates with pharmaceutical partners on other transdermal projects.
In March 2024, it announced a development collaboration agreement with Bayer to create a patch product for an already-approved oral medicine.
Newsletter
Sign up for free weekly updates
The latest femtech news, research and investment, straight to your inbox.










